Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26811482 | 0.88 | L3MBTL1 (0.50) | L3MBTL1PKMALDH1A1TDP1KMT2A | |
| SCHEMBL25612343 | 0.87 | L3MBTL1 (0.49) | L3MBTL1PKMALDH1A1TDP1KMT2A | |
| SCHEMBL25612345 | 0.87 | L3MBTL1 (0.49) | L3MBTL1PKMALDH1A1TDP1KMT2A | |
| SCHEMBL28376763 | 0.80 | L3MBTL1 (0.52) | L3MBTL1PKMALDH1A1TDP1KMT2A | |
| SCHEMBL8628655 | 0.79 | POLB (0.65) | L3MBTL1PKMALDH1A1TDP1KMT2A | |
| SCHEMBL30642435 | 0.77 | HPGD (0.45) | L3MBTL1PKMALDH1A1TDP1KMT2A | |
| SCHEMBL26623862 | 0.77 | HPGD (0.45) | L3MBTL1PKMALDH1A1TDP1KMT2A | |
| SCHEMBL20449219 | 0.77 | L3MBTL1 (0.49) | L3MBTL1PKMALDH1A1TDP1KMT2A | |
| SCHEMBL18981747 | 0.77 | L3MBTL1 (0.49) | L3MBTL1PKMALDH1A1TDP1KMT2A | |
| SCHEMBL15129368 | 0.77 | L3MBTL1 (0.44) | L3MBTL1PKMALDH1A1TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-30 | — | — | US | disclosed |
| WO-2023102228-A1 | HETEROCYCLIC COMPOPUNDS AS GCN2 AND PERK KINASE INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | EIF2AK4, GCN1, EEF2K | L3MBTL1 970/4885PKM 636/4885ALDH1A1 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.